[Form 4] Jupiter Neurosciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Jupiter Neurosciences (JUNS) Form 4 filing: President, Chief Business Officer and Director Alison D. Silva reported three open-market purchases on 01 July 2025 totaling 750 common shares at an average price of roughly $1.03 per share. Following the transactions, Silva directly owns 112,777 shares of JUNS common stock. No derivative security activity was disclosed.

The transactions are coded “P,” indicating routine open-market buys and not part of a Rule 10b5-1 trading plan. While the dollar value is modest (≈ $770), insider buying is generally interpreted as a vote of confidence in the company’s prospects. However, the size of the purchase is immaterial to overall share count and does not meaningfully affect ownership structure.

Positive

• Insider confidence: Director/Officer purchased 750 shares in the open market, suggesting personal optimism.

Negative

• Immaterial size: Purchase value (~$770) is too small to influence ownership structure or market perception materially.

Insights

Financial Analyst

TL;DR: Small insider buy; positive signal but immaterial to valuation.

Silva’s acquisition of 750 shares (~$770) marginally lifts her stake to 112,777 shares. Insider purchases often align management interests with shareholders and may imply optimism. Nevertheless, the purchase represents an insignificant fraction of JUNS’s outstanding shares and will not alter liquidity, capital structure, or earnings per share. Investors may view it as a mild sentiment uptick rather than a catalyst. Overall impact: routine.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Silva Alison D.

(Last) (First) (Middle)

C/O JUPITER NEUROSCIENCES, INC.

1001 NORTH US HYWAY 1, SUITE 504

(Street)

JUPITER FL 33477

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
JUPITER NEUROSCIENCES, INC. [ JUNS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Pres + Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2025		P		250	A	$1.0263	112,277	D
Common Stock	07/01/2025		P		250	A	$1.0287	112,527	D
Common Stock	07/01/2025		P		250	A	$1.034	112,777	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Alison Silva	07/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Alison D. Silva purchase in the latest JUNS Form 4?

She bought 750 shares of Jupiter Neurosciences common stock on 01 Jul 2025.

At what prices were the JUNS shares acquired?

The three trades were executed at $1.0263, $1.0287, and $1.034 per share.

How many JUNS shares does Alison D. Silva now own?

After the transactions, she directly owns 112,777 common shares.

Were any derivative securities involved in this Form 4 filing?

No. No options, warrants, or other derivatives were reported.

Does the filing indicate a Rule 10b5-1 trading plan?

No. The trades are coded "P" (open-market purchase) and the Rule 10b5-1 checkbox is unchecked.